Osaic Holdings
SPRY icon

Osaic Holdings’s ARS Pharmaceuticals SPRY Stock Holding History

Osaic Holdings’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Sell
2,997
-695
-19% -$5.98K ﹤0.01% 6033
2026
Q1 		$29.6K Buy
3,692
+66
+2% +$633 ﹤0.01% 5588
2025
Q4 		$42.2K Sell
3,626
-502
-12% -$4.88K ﹤0.01% 5354
2025
Q3 		$42.8K Sell
4,128
-1,087
-21% -$15.6K ﹤0.01% 5412
2025
Q2 		$91K Buy
5,215
+1,803
+53% +$26K ﹤0.01% 4589
2025
Q1 		$42.9K Sell
3,412
-8,936
-72% -$108K ﹤0.01% 4836
2024
Q4 		$130K Buy
12,348
+9,896
+404% +$139K ﹤0.01% 3984
2024
Q3 		$35.6K Buy
2,452
+2,344
+2,170% +$27.9K ﹤0.01% 4985
2024
Q2 		$918 Sell
108
-656
-86% -$5.82K ﹤0.01% 6839
2024
Q1 		$7.81K Buy
764
+91
+14% +$678 ﹤0.01% 5888
2023
Q4 		$3.69K Buy
+673
New +$2.95K ﹤0.01% 6288
2023
Q1 		– Sell
-2,000
Closed -$17K – 7568
2022
Q4 		$17K Hold
2,000
– – ﹤0.01% 5682
2022
Q3 		$11K Buy
+2,000
New +$9.86K ﹤0.01% 5979

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Osaic Holdings's SPRY Position: Q2 2026 in Review

Osaic Holdings reduced its ARS Pharmaceuticals (SPRY) stake by 19% in Q2 2026, selling an estimated $5.98K and leaving 2,997 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #6033.

Osaic Holdings first reported a position in SPRY in Q3 2022 and has held it in 13 quarters since. The position peaked at $130K in Q4 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Osaic Holdings held 2,997 shares of ARS Pharmaceuticals worth $24K as of Q2 2026.
  • Osaic Holdings sold 695 ARS Pharmaceuticals shares in Q2 2026, an estimated $5.98K.
  • ARS Pharmaceuticals made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6033 holding.
  • Osaic Holdings first reported a position in ARS Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Osaic Holdings's ARS Pharmaceuticals position peaked at $130K in Q4 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.